Keros Therapeutics (KROS) Current Assets (2019 - 2025)

Keros Therapeutics has reported Current Assets for 7 years, with the latest figure at $315.4 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets fell 46.44% year-over-year to $315.4 million; the trailing twelve-month figure through Dec 2025 stood at $315.4 million (down 46.44% YoY), and the FY2025 full-year result was $315.4 million, down 46.44% from the prior year.
• Current Assets for Q4 2025 stood at $315.4 million, down from $719.3 million in the prior quarter.
• The five-year high for Current Assets was $759.5 million in Q1 2025, with the low at $222.4 million in Q2 2022.
• Historically, Current Assets has averaged $393.6 million across 5 years, with a median of $324.9 million in 2023.
• Annual changes were most pronounced in 2021 — Current Assets jumped 337.28% — and 2025, when it slumped 46.44%.
• Keros Therapeutics' Current Assets stood at $251.4 million in 2021, then gained by 13.65% to $285.8 million in 2022, then grew by 21.53% to $347.3 million in 2023, then soared by 69.57% to $588.9 million in 2024, then tumbled by 46.44% to $315.4 million in 2025.
• The last three Current Assets figures came in at $315.4 million (Q4 2025), $719.3 million (Q3 2025), and $732.8 million (Q2 2025), per Business Quant data.